Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MILE: mifepristone + letrozole versus methotrexate for ectopic pregnancy
2023-503935-16-00Phase 2Authorised
- Sponsor
- Karolinska Institutet
- Start
- Dec 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised trial in Ectopic pregnancy (EP) comparing Mifepristone + letrozole with Methotrexate (2 arms). Primary endpoint: Successful treatment response within 60 days. Planned start Dec 2023; status: authorised.
02
Drugs
mifepristoneletrozolemethotrexate
03
Conditions
Ectopic pregnancy (EP)
Beyond the preview
Go deeper on 2023-503935-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503935-16-00.